A clear, colorless liquid supplied in a colorless, transparent vial

Meningococcal Serogroup A Polysaccharide Tetanus Toxoid Conjugate [Strain: N. meningitidis group A, Carrier protein strain: C. tetani] 10 μg, Meningococcal Serogroup C Polysaccharide Tetanus Toxoid Conjugate [Strain: N. meningitidis group C, Carrier protein strain: C. tetani] 10 μg, Meningococcal Serogroup Y Polysaccharide Tetanus Toxoid Conjugate [Strain: N. meningitidis group Y, Carrier protein strain: C. tetani] 10 μg, Meningococcal Serogroup W Polysaccharide Tetanus Toxoid Conjugate [Strain: N. meningitidis group W, Carrier protein strain: C. tetani] 10 μg in one vial (0.5mL)

Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 6 weeks of age through 55 years of age

Method of Administration

Administer a single dose of 0.5 mL intramuscularly into the deltoid region or anterolateral thigh, depending on the recipient`s age and muscle mass.

Do not administer intradermally or subcutaneously.

Age and Schedule

Infants 6 weeks through less than 6 months of age: 4 doses (The primary 3-dose series is administered at least 8 weeks apart; the 4th dose is administered at least 6 months after the 3rd dose and at or after 12 months of age).

Infants 6 months through less than 24 months of age without prior meningococcal vaccination: 2 doses (Given at least 3 months apart; the 2nd dose is administered at or after 12 months of age).

2 through 55 years of age: A single dose.

1 vial/box [Vial (0.5 mL)]

Store in a tightly closed container at 2~8℃. Avoid freezing.